Fujifilm (OTCMKTS:FUJIY) Share Price Passes Above 200-Day Moving Average - What's Next?

Key Points

• Fujifilm's stock has crossed above its 200-day moving average of $10.46, with recent trading peaking at $12.20 and closing at $12.16.
• Wall Street Zen has dropped its rating on Fujifilm shares from "buy" to "hold" as of May 23rd.
• Fujifilm reported earnings of $0.15 per share, meeting analyst expectations, with revenues totaling $5.08 billion for the last quarter.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.46 and traded as high as $12.20. Fujifilm shares last traded at $12.16, with a volume of 160,006 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Fujifilm from a "buy" rating to a "hold" rating in a research note on Friday, May 23rd.

Fujifilm Stock Down 1.2%

The business has a 50-day moving average price of $10.81 and a two-hundred day moving average price of $10.48. The company has a quick ratio of 0.92, a current ratio of 1.40 and a debt-to-equity ratio of 0.14. The firm has a market cap of $29.55 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 3.64 and a beta of 0.67.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The technology company reported $0.15 earnings per share for the quarter, hitting analysts' consensus estimates of $0.15. Fujifilm had a return on equity of 7.73% and a net margin of 7.93%.The business had revenue of $5.08 billion for the quarter, compared to analyst estimates of $760.41 billion. On average, equities research analysts expect that Fujifilm Holdings Corp. will post 0.66 EPS for the current year.

Fujifilm Company Profile

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.